A Step Forward for Pertussis Prevention: BioNet’s “Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial” Published in Vaccine.

Key Highlights
🎯 A total of 102 healthy Australian adults aged 18–30 years participated in this randomized, controlled clinical trial, which compared BioNet’s stand-alone acellular pertussis vaccine (aP2), containing pertussis toxin (PT) and filamentous hemagglutinin (FHA), with a licensed Tdap vaccine.
🎯 The study successfully met its primary objective, demonstrating that BioNet aP2 was non-inferior to the comparator vaccine in generating immune responses against pertussis antigens.
🎯 BioNet aP2 elicited higher PT antibody responses and neutralizing antibodies than the comparator vaccine at both 28 days and one year after vaccination, indicating strong and durable immune responses.
🎯 Enhanced immune responses were observed among adults primed in infancy with either whole-cell pertussis or acellular pertussis vaccines.
🎯 BioNet’s stand-alone acellular pertussis vaccine demonstrated a favorable safety profile, with adverse events generally mild to moderate in severity. No vaccine-related serious adverse events were reported during the one-year follow-up period.

Read the full publication: Vaccine